Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Parkinson's Disease
100%
Levodopa Therapy
100%
Subthalamic nucleus Deep Brain Stimulation (STN-DBS)
100%
Apomorphine Infusion
100%
Subthalamic Stimulation
100%
Apomorphine
83%
Intrajejunal Levodopa Infusion
83%
Non-motor Symptoms
50%
Rating Scales
33%
Quality of Life
33%
Motor Symptoms
33%
Parkinson Patients
33%
Real-life Cohort
33%
Levodopa Equivalent Dose
33%
Clinical Characteristics
16%
Sexual Behavior
16%
Relative Change
16%
Demographic Characteristics
16%
Clinical Efficacy
16%
Gastrointestinal Diseases
16%
Multiple Comparisons
16%
Treatment Options
16%
Multiple Treatments
16%
Hallucinations
16%
Treatment Choice
16%
Number-needed-to-treat
16%
Parametric Test
16%
Attention Memory
16%
Propensity Score Matching
16%
Symptom Assessment
16%
Unified Parkinson's Disease Rating Scale (UPDRS)
16%
Non-motor
16%
Paired T-test
16%
Wilcoxon Signed-rank Test
16%
Neuropsychiatric
16%
Observation Study
16%
Movement Disorder Society
16%
Parkinson's Disorder
16%
Motor Outcome
16%
Domain Analysis
16%
Change Effect
16%
Treatment Scale
16%
Medicine and Dentistry
Infusion
100%
Parkinson's Disease
100%
Apomorphine
100%
Levodopa
100%
Unified Parkinson's Disease Rating Scale
37%
Quality of Life
25%
Symptom
25%
Effect Size
12%
Urinary System
12%
Gastrointestinal Distress
12%
Hallucination
12%
Numbers Needed to Treat
12%
Parametric Test
12%
Student T Test
12%
Symptom Assessment
12%
Stereotypic Movement Disorder
12%
Propensity Score Matching
12%
Neuroscience
Parkinson's Disease
100%
Apomorphine
100%
L-DOPA
100%
Hallucination
12%
Stereotypic Movement Disorder
12%